Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT06380751 |
| Title | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) |
| Acronym | EvoPAR-BR01 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | CAN |